Join to view full profile
201 North Broadway StreetViragh BLDG 5th FLBaltimore, MD 21287
Phone+1 410-955-8964
Fax+1 410-367-2194
Dr. Carducci is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael Carducci is an oncologist based in Baltimore, MD, specializing in hematologic oncology, prostate cancer, vulvar carcinoma, gynecologic oncology, and urologic oncology. He completed his medical education at Wayne State University School of Medicine followed by a residency in Internal Medicine at the University of Colorado and a fellowship in Hematology and Medical Oncology at Johns Hopkins University. Dr. Carducci has contributed to several publications in prominent journals, including the Journal of Clinical Oncology and Cancers. His clinical trials experience includes studies on prostate cancer therapies and advanced renal cell carcinoma. He has received multiple CMS Meaningful Use Certifications from Epic Systems Corporation between 2013 and 2017.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1992 - 1995
University of ColoradoResidency, Internal Medicine, 1988 - 1992
Wayne State University School of MedicineClass of 1988
Certifications & Licensure
MD State Medical License 1992 - 2028
VA State Medical License 2022 - 2028
DC State Medical License 2012 - 2027
CO State Medical License 1990 - 1993
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
Clinical Trials
- Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma
- Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
- Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer Start of enrollment: 2002 Apr 25
Publications & Presentations
PubMed
- Interconnectedness of Factors Affecting Patient Willingness to Discuss Prostate Cancer Clinical Trials With Physicians.Janaka S S Liyanage, Vy Ong, Lauren M Hamel, Susan Eggly, Michael A Carducci
JCO Oncology Practice. 2026-08-24 - Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Do...Susan Halabi, Bin Luo, Chenxi Yu, Larysa H M Rydzewska, Akash Roy
European Urology Focus. 2026-06-01 - Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.Laura M Linville, Jenna V Canzoniero, Catherine H Marshall, Deborah K Armstrong, Mark C Markowski
Clinical Advances in Hematology & Oncology. 2026-06-01
Other
- Investigational approaches for the treatment of advanced prostate cancerCarducci MA, Antonarakis ES, Walczak JR, Pili R
http://www.uptodate.com/contents/investigational-approaches-for-the-treatment-of-advanced-prostate-c
UpToDate, Wolters Kluwer Health - 2013-04-10
Press Mentions
Intervention to Improve Patient-Physician Communication May Improve Black Patient Participation in Clinical Trials, Study Led by Karmanos ResearcherFebruary 27th, 2023
Dramatic Results Seen with Bone-Protecting Agents in Prostate Cancer PatientsJune 5th, 2019
Trials Back Earlier Use of Androgen Receptor InhibitorsJune 3rd, 2019
Grant Support
- The Johns Hopkins Translational Science Team and Consortium for ETCTN StudiesJOHNS HOPKINS UNIVERSITY2026–2027
- Phase I Clinical Trials Of New Anti-Cancer Targeted TherapiesNational Cancer Institute2008–2012
- DSMNational Cancer Institute2006–2010
- Phase I Clinical Trials Of New Anti-Cancer Targeted TherNational Cancer Institute2003–2007
- Foreign Accrual For U01ca70095 - 2006 Load.National Cancer Institute2006
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/michael-carducci
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
